对修改的固定剂量四因子前激素复合物缩剂的评估,用于华法林逆转
Meghan E Peterson1, Megan P Jaynes2, Sarah Berardi2
1Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA. meghan.peterson@vumc.org.
Journal of thrombosis and thrombolysis
|April 6, 2024
概括
一种修改的固定剂量四因子前激素复合物缩物 (4F-PCC) 在危及生命的出血患者中有效逆转华法林. 与传统的基于体重和INR的疗法相比,这种方法可以降低剂量和成本,同时保持有效性和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 紧急医疗 紧急医疗
背景情况:
- 四因子前激素复合缩物 (4F-PCC) 是在危急出血中逆转华法林的标准.
- 目前的剂量取决于体重和INR,导致延迟.
- 为了提高效率和有效性,正在探索替代剂量策略.
研究的目的:
- 为了评估药剂师驱动的,固定剂量的4F-PCC疗法与用于华法林逆转的标准剂量相比.
- 评估实现INR小于2的首要结果.
- 为了比较二次结果,包括剂量,成本,时间,维生素K的使用,以及血栓发生率.
主要方法:
- 追溯,单中心,前后协议分析.
- 与修改的固定剂量 (1500 IU) 4F-PCC疗法与基于体重和INR的剂量进行了比较.
- 包括195名患者 (74名前队,121名后队) 患有危及生命的出血在华法林.
主要成果:
- 主要终点 (INR <2) 在92% (前) 和95% (后) (p=0.097) 中实现.
- 通过固定剂量治疗方案显著降低了4F-PCC中位数剂量和成本 (p < 0.001).
- 血栓塞栓事件没有显著差异 (3对8,p=0.453).
结论:
- 1500 IU固定剂量的4F-PCC对大多数患者的华法林逆转是有效的.
- 这种方案可以快速实现目标INR,并降低成本.
- 固定剂量策略表明,在血栓形成风险方面,与标准剂量相比,安全性相当.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Hepatic Drug Clearance: Effect of Protein Binding
194
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
194
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K


